Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Premenopausal Breast Cancer × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 392 Melanoma 256 Squamous Cell Carcinoma of Head and Neck 198 Parkinson Disease 4, Autosomal Dominant Lewy Body 162 Neoplasms 154 Breast Neoplasms 143 Triple Negative Breast Neoplasms 138 Neoplasm Metastasis 133 Colorectal Neoplasms 126 Lung Neoplasms 124 Carcinoma, Renal Cell 114 Head and Neck Neoplasms 102 Ovarian Neoplasms 94 Stomach Neoplasms 89 Carcinoma, Transitional Cell 76 Pancreatic Neoplasms 72 Urinary Bladder Neoplasms 70 Carcinoma, Hepatocellular 63 Endometrial Neoplasms 60 Uterine Cervical Neoplasms 57 Esophageal Neoplasms 53 Recurrence 46 Prostatic Neoplasms 43 Carcinoma 39 Glioblastoma 37 Sarcoma 36 Carcinoma, Squamous Cell 35 Lymphoma 32 Fallopian Tube Neoplasms 32 Small Cell Lung Carcinoma 31

Interventions

pembrolizumab 1 exemestane 1 Tamoxifen 1 Surgical Procedures, Operative 1 Leuprolide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02990845 2023-02-22

PEER

National Taiwan University Hospital

Phase 1/2 Terminated

Premenopausal Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡